MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.500
0.000
0.00%
Closed 16:00 04/02 EDT
OPEN
1.490
PREV CLOSE
1.500
HIGH
1.570
LOW
1.480
VOLUME
48.34K
TURNOVER
--
52 WEEK HIGH
5.73
52 WEEK LOW
1.480
MARKET CAP
40.80M
P/E (TTM)
19.74
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MDWD stock price target is 7.10 with a high estimate of 10.00 and a low estimate of 5.50.

EPS

MDWD News

More
  • MediWound Provides Corporate Update Related to COVID-19 Pandemic
  • GlobeNewswire · 3d ago
  • Covid-19 activity roundup - healthcare
  • Seeking Alpha - Article · 3d ago
  • 108 Biggest Movers From Yesterday
  • Benzinga · 03/11 09:34
  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
  • Benzinga · 03/10 13:19

Industry

Pharmaceuticals
+2.64%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About MDWD

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
More

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.